Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038978 | 0.97 | KDM4E (0.58) | KDM4EHSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL6039100 | 0.94 | KDM4E (0.60) | KDM4EHSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL6039170 | 0.89 | KDM4E (0.67) | KDM4EHSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL6038873 | 0.89 | KMT2A (0.62) | KDM4EHSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL6038686 | 0.88 | KDM4E (0.55) | KDM4EHSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL6038558 | 0.88 | KDM4E (0.50) | KDM4EHSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL6039279 | 0.87 | KDM4E (0.54) | KDM4EHSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL6038747 | 0.86 | KDM4E (0.61) | KDM4EHSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL6038512 | 0.86 | KDM4E (0.69) | KDM4EHSD17B10LMNAKMT2AMEN1 | |
| SCHEMBL6038603 | 0.85 | KMT2A (0.63) | KDM4EHSD17B10LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | KDM4E 3561/4885HSD17B10 2083/4885LMNA 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.